ProCE Banner Activity

Phase III PlanB Final Analysis: Adjuvant TC vs EC→T in Pts With High-Risk HER2-Negative Early Breast Cancer

Slideset Download
Conference Coverage
TC noninferior to EC→T in patients with high-risk HER2-negative early BC with comparable 5-year DFS (90%), OS (95%), and reduced toxicity.

Released: June 12, 2017

Expiration: June 11, 2018

No longer available for credit.

Share

Provided by

Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants by

AbbVie

Amgen, Inc.

AstraZeneca

Celgene

Genentech Roche Virology

Halozyme

Incyte

Merck Oncology